Izhodišče: Prikazujemo rezultate naše skupine bolnikov z bikuspidno aortno (BAV) stenozo, ki smo jim perkutano vstavili umetno aortno zaklopko.
Introduction
Bicuspid aortic valve (BAV) has been considered a relative contraindication for transcatheter aortic valve implantation (TAVI) mainly because of the theoretical risk for uneven and incomplete prosthesis expansion and wall apposition, resulting from calcium asymmetric distribution in the annulus, commissures, and aortic valve leaflets, which will eventually lead to consequent increased rate of prosthesis malfunction and paravalvular regurgitation.
Although there are reports describing the feasibility of TAVI in patients with BAV, experience remains restricted, often referred to multicentre cohorts, and with limited mid-term follow-up information (1) (2) (3) (4) (5) (6) (7) (8) . We present our experience focusing on preoperative BAV anatomical data, perioperative findings, and intermediate-term clinical results.
Methods
Perioperative and intermediate-term follow-up data of all patients with BAV treated consecutively with TAVI from May 2008 to April 2014 at the Deutsches Herzzentrum Berlin, Berlin, Germany, were retrospectively analysed. Type of BAV, annular geometry, calcium distribution, and calcium amount were all recorded. All patients had signed consent to the procedure and to the processing of their data for medical and scientific purposes.
BAV Classification
Aortic valves were classified as bicuspid according to preoperative multislice computed tomography and transoesophageal echocardiography and were arranged in 3 groups (9) . Fusion of two of the three aortic leaflets was observed in all patients. If the fusion occurred between the right and the left coronary cusps, the BAV was classified as type 1. Similarly, type 2 BAV included fusion of the right-and non-coronary leaflets, whereas fusion of the left-and non-coronary cusps was classified as type 3 BAV. Moreover, the presence or absence of a raphe was marked with a "+" or a "-" , respectively (placed next to the valve type). 
Srce in ožiLje

Geometrical Annular Data
Geometrical annular information was analysed using multi-slice cardiac computed tomography. Measures included: aortic valve (AV) annulus at the insertion of the aortic cusps (perimeter derived diameter, major and minor axis), native AV area, LVOT, aortic root, sinotubular junction and ascending aorta maximal diameters. The annular ellipticity index (EI) was calculated as the ratio between the semiminor and the semi-major aortic annulus axis (EI = b/a, where a is semi-major and b is semi-minor axis). We also calculated linear and numeric eccentricity, as previously described by our group (10).
Aortic Unit Calcification
Information about calcification score were obtained from multi-slice computed tomography and expressed as the AV and LVOT calcified volumes. Moreover, the calcification area and distribution on each of the cusps was also evaluated. Measurements were performed automatically using the dedicated planning workflow from the software 3mensio Valves® (Pie Medical Imaging BV, Maastricht, the Netherlands).
Implantation Technique
Two different prostheses were implanted: transapical Edwards SAPIEN® valve (Edwards Lifesciences, Inc., Irvine, California) and transfemoral Medtronic CoreValve® (Medtronic, Inc., Minneapolis, Minnesota). All procedures were performed under general anaesthesia and following previously described and established protocols (11) (12) (13) . Rules for prostheses sizing did not differ from those normally applied for TAVI in tricuspid AV stenosis (14) .
Perioperative and Follow-up Evaluation
Perioperative results were collected and procedural success/complications were classified following the Valve Academic Research Consortium (VARC) recommendations.
Intraoperative trans-oesaphageal and pre-discharge trans-thoracic echocardiography were performed. Paravalvular and valvular regurgitation was calculated and classified as mild (I), moderate (II), and severe (III) according to semiquantitative and quantitative parameters (15) .
Trans-prosthetic gradients were calculated together with indexed effective orifice areas (EOAi) and eventual patient prosthesis mismatch (PPM) (16) .
Clinical follow-up through outpatient visits (one month after discharge) and telephone contacts (after rehabilitation and one year after the procedure) was performed.
Statistical Analysis
Data are presented as absolute numbers, percentages, and mean ± standard deviation.
Patients without and with residual paravalvular leak ≥ 1 at the end of TAVI were compared.
Comparisons were also performed with patients that required prosthesis re-ballooning, second valve implanta- 
Results
Perioperative
A total of 33 patients (13 females and 20 males) were treated. Preoperative patients and AVs data are reported in Table 1 and Figures 1-2 . Moreover, Table 2 summarizes intraoperative data. The majority of patients were treated by means of transapical Edwards SAPIEN® valve. Nine patients (27.3 %) required post-ballooning of an implanted valve for moderate to severe paravalvular leak occurrence. Three patients required a second valve implantation (9 %) for persistent severe paravalvular leak that became mild after re-valving. Two conversions (6 %) to conventional surgery were necessary. One patient had malpositioning of a self-expandable valve with structural damage of the prosthesis during implantation. The second patient experienced annular rupture during implantation of a balloon expandable valve. Table 3 includes the intraoperative echocardiography together with the clinical outcome data. At the end of the procedure, mild paravalvular leak was noticed in 12 patients (36.4 %) and moderate paravalvular leak in one patient (3 %). Central AV regurgitation was reported in one patient (3 %). PPM was moderate in 5 patients (15 %) and no patient developed severe PPM. The device No patient died in the first 30 days after the procedure. Two patients (6 %) died in a different institution because of pneumonia and sepsis during the postsurgical rehabilitation, both 6 weeks after discharge.
When comparing anatomical variables of patients without and with ≥ 1 residual paravalvular leak at the end of the procedure, there was a trend for larger aortic annular diameter and valve area in patients that developed paravalvular leak (Table 4) . Moreover, a trend for higher valve calcium volume with higher distribution in the right and left coronary leaflets was noticed in patients that developed paravalvular leak. Operative time was significantly longer in patients that developed paravalvular leak. Prosthesis performance, in terms of transvalvular gradient, effective orifice area and eventual PPM, was similar in both groups (Table 4) .
Moreover, a sub-analysis of patients that required re-ballooning (9 patients), re-valving (3 patients), and conversion to conventional surgery (2 patients) was performed. Although there were no significant differences in terms of valve anatomy, ellipticity, calcium distribution, and calcium content, these patients had significantly larger native annular area, perimeter, and perimeter derived diameter when compared to the remaining patients (27.6 ± 2.1 mm vs. 24.8 ± 3.0 mm; p = 0.01).
Follow-up
Clinical follow-up was complete in all patients and average duration was 20 ± 15 months (1-70 months). Overall two-year estimated survival was 70 % (CI: 52.7-93.1) (Figure 3 ). There were no reported cardiac deaths. No patient re- 
Discussion
The occurrence of BAV in patients with severe AV stenosis may represent a theoretical challenge for TAVI. In fact, this anatomic variation that is present in at least 50 % of patients submitted to conventional AV replacement (17) has been considered, per se, an exclusion criterion for TAVI (18) .
In patients with BAV, a potential risk of TAVI is mainly in an uneven expansion of the prosthesis, resulting from the heterogeneous pliability of the native valve and the particular stiffness of the leaflet where a raphe is present.
Zegdi et al. (19) have proven these important theoretical drawbacks of TAVI in a group of 16 BAV patients where a self-expandable stent, specifically designed for stented valves, was deployed intraoperatively inside the aortic valve before undergoing AV resection for conventional surgical aortic valve replacement. Elliptic stent deployment and under-deployment were the rule in BAV. In a second phase, the authors performed an ex vivo study of a "homemade" stented valve to confirm that the regularity of the coaptation line was dependent on the quality of stent deployment (20) .
Zegdi report, although of seminal importance, presents some differences from the daily TAVI practice. First, it does not include a phase of balloon valvuloplasty before stent deployment within the native AV annulus. Secondly, it is focused on the anatomical adaptation of a selfexpandable stent and does not take into consideration the dynamics of balloon expandable stents. Finally, it considers the ex vivo behavior of a "homemade" stented AV prosthesis that may differ greatly from the in vivo performance of the TAVI prostheses currently available on the market. In fact, despite the described important theoretical drawbacks, TAVI has been applied, although in limited numbers, in BAV patients at prohibitive risk for conventional surgery. Published experiences have mainly described acute and mid-term results with both balloon expandable and self-expandable TAVI prostheses. In these patients, occurrence of more than moderate aortic regurgitation ranges from 0 to 32 % with mean trans-valve pressure gradients always below 15 mmHg (1-8).
Mylotte et al. have reported the multicenter results of TAVI in BAV. In a total of 139 patients procedural mortality was 3.6 %, with valve embolization in 2.2 % and conversion to surgery in 2.2 %. Post-implantation aortic regurgitation grade ≥ 2 occurred in 28.4 % but was prevalent in only 17.4 % when CT-based TAVI sizing was performed. One-year mortality was 17.5 % (7).
Bauer et al. evaluated 38 patients with BAV within the German TAVI registry, and have compared them with a cohort group of 1357 tricuspid aortic valve patients. Although TAVI outcomes were satisfactory in both groups, the occurrence of ≥ grade 2 AR was significantly more common in BAV (25 % vs. 15 %). Thirty-day mortality rate was similar in both cohorts and BAV was not associated with higher 1-year mortality rate (6) . In a case-match study, Kochman et al. compared 28 BAV with 84 tricuspid valve patients (1:3 ratio), implanted with both balloon expandable and selfexpandable prostheses. There was a statistically insignificant trend for higher post-procedural mean pressure gradient (11.5 ± 6.4 vs. 10.4 ± 4.5 mm Hg) and aortic regurgitation grade ≥ 2 (32 % vs. 23 %) in the BAV patients that did not result in an increased 30-day and 1-year all-cause mortality (5).
More recently Costopoulos et al. have shown more concerning results in a multicenter experience. When comparing TAVI in 21 BAV versus 447 tricuspid AV patients, the authors noticed a trend toward a lower device success rate (85.7 % vs. 94.4 %) and significantly higher 30-day mortality rate (14.2 % vs. 3.6 %) in the BAV group (4) .
Finally, in the most recent multicenter evaluation proposed by Yousef et al. (8) , the authors present results in 108 patients with BAV treated by TAVI within the premises of 21 centres. The composite primary outcome, according to VARC criteria, occurred in one quarter of patients (26.9 %) and was mainly driven by re-intervention for valve malposition (9.3 %).
Although the topic TAVI in BAV has been already analyzed in details, the present manuscript presents the largest single center experience with an extended follow-up. All cases were performed within the premises of a facility that has had a consistent exposure to TAVI since its very early introduction. Our results confirm what has been previously shown by others and clearly demonstrate that, although TAVI for BAV has become a standard procedure, challenges should be expected, even in most experienced centres.
We have recently reported our 5-year experience with trans-apical TAVI, including over 700 patients. In our global experience, conversion to surgical aortic valve implantation due to rupture of the device landing zone or coronary artery obstruction was reported in 1.1 % of the cases (6 % in the BAV series), prosthesis re-dilatation for more than mild paravalvular leak in 7.5 % (27 % in the BAV series), and re-valving in 2.2 % (9 % in the BAV series) (13) .
Valve hemodynamics in BAV patients were also quite different, when compared to those reported in our overall experience. At the end of the procedure, mild regurgitation was present in 19.2 %, and moderate regurgitation in 0.8 % of the patients included in our overall experience (13) . In our sub-group of BAV patients, mild and moderate paravalvular leaks occurred in a slightly higher rate (36 % and 3 % respectively).
Although the presence of residual paravalvular leak ≥ 1 did not impact upon acute and intermediate-term (2-year) survival, these findings may be biased by the very limited sample size. In fact, there is emerging and consistent evidence that even the presence of mild prosthetic regurgitation after TAVI may impact significantly upon long-term clinical outcomes (21) .
From an inferential standpoint, we were not able to identify any specific anatomical reason that could have increased the risk of TAVI failure in BAV patients. In particular, calcification distribution and calcification amount did not seem to differ significantly in patients that had residual paravalvular leak and/or required further intervention. Furthermore, although "ellipticity" was not found to be a predictor of outcome, the sample size and the contained number of valves that were truly elliptic should be considered as a major limitation of the present study.
Interestingly, we have noticed a trend for larger annular anatomy in patients developing mild paravalvular leak. Moreover, we have reported significantly larger native annuli in patients requiring further intervention (re-ballooning, re- valving, and conversion) for persistent moderate to severe paravalvular leak. Finally, some comments should be given concerning the risk of inappropriate prosthesis expansion with consequent valve malfunction in patients with BAV undergoing TAVI.
In this context, some authors have described a PPM rate after TAVI for tricuspid AV stenosis ranging from 40 to 60 % (22, 23) . In our experience, moderate and severe PPMs occurred respectively in approximately 27 % and 8 % of patients undergoing TAVI for severe stenosis of a tricuspid AV (24) . In the present series of BAV patients moderate PPM was present in only 15 % of patients and no patient experienced severe PPM.
One should take into account also the limitations of our article: this was a single-centre retrospective analysis of a relatively small cohort of patients whose BAV have had different, morphological types. Prospective studies are needed and cooperation between institutions with large numbers would be required to enlarge the study population numbers.
In conclusion, although TAVI in BAV is feasible, it is associated with an increased rate of implantation failures and caution should be advised when treating these patients, even in the premises of very experienced centres. The present manuscript presents results achieved with balloon expandable and self-expandable prostheses belonging to an earlier generation of devices. Outcomes may be different once new generation TAVI prostheses, including those that are fully retrievable and repositionable, are tested consistently in this challenging aortic anatomical scenario.
